The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.
Phase 4
Completed
- Conditions
- Healthy
- Registration Number
- NCT00409903
- Lead Sponsor
- Regional Hospital Holstebro
- Brief Summary
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in healthy individuals - during baseline conditions and after activation of the sympathetic nervous system.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- Both genders.
- Age 18 - 65 years.
- Body mass index less or equal to 30 kg/m2.
- Women must use oral hormonal anticonception, use intrauterine anticonceptive device, be sterilized/hysterectomized or be postmenopausal.
Exclusion Criteria
- History or clinical signs of heart, lung, kidney, or endocrine organ disease.
- Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose.
- Abnormal screening of the urine regarding: albumin and glucose
- Malignant disease.
- Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic.
- Alcohol abuse.
- Smoking.
- Drug use or abuse.
- Known intolerance or allergy to eprosartan or sodium nitroprusside.
- Blood donation within 1 month of the start of the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Heart rate Fractional sodium excretion Plasma levels of noradrenaline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Medical Research, Holstebro Hospital
🇩🇰Holstebro, Denmark